iShares U.S. Medical Devices ETF (IHI)

The iShares U.S. Medical Devices ETF (ticker IHI) buys stock in the manufacturers of medical equipment and implants — the firms that make hip replacements, heart stents, surgical instruments, dialysis machines, diagnostic imaging systems, and all the durable goods that hospitals and clinics use to diagnose and treat patients.

Medical devices are the hardware of healthcare — the implants, machines, and instruments that doctors use to fix bodies. Unlike drugs, which are consumed once and replaced, devices are often durable goods that a hospital buys once and uses for years, or in the case of implants, that patients receive and keep for a lifetime. This makes the device business fundamentally different from pharma. Where a drug company sells the same pill to millions of people, a device company often sells dozens of variants — different sizes of hip implants, different catheters for different vessels, different dialyzers for different kidney-failure patients. The business is high-touch, solution-oriented, and deeply entangled with hospital workflows.

IHI gives you a basket of the companies playing this game at scale. The biggest holdings are likely to be names like Johnson & Johnson’s device division, Medtronic, Abbott, Boston Scientific, Stryker, Zimmer Biomet, and Intuitive Surgical — the titans that operate across many device categories and have the scale to negotiate with large hospital systems. But the fund also holds smaller companies that dominate specific niches: orthopedic-implant specialists, makers of surgical robots, diagnostic-equipment firms, patient-monitoring companies, and so on.

The reason investors own a device ETF is that the business model is attractive. Once a hospital or surgeon adopts a device (say, a particular brand of knee implant or a dialysis machine), switching costs are high. The surgeon knows how to use it, the hospital has trained staff around it, and patients may have received the device and want compatible replacements or supplies. This gives device makers pricing power and recurring revenue — not as pure as a software subscription, but far more durable than a commodity business. A hospital that buys 500 knee implants a year from one vendor tends to stick with that vendor unless the quality drops or price rises unacceptably.

The aging of populations in developed countries is also a structural tailwind. More people over 65 means more joint replacements, more heart problems requiring stents or pacemakers, more need for diagnostic imaging and monitoring equipment. Unlike drugs, which can sometimes be avoided through lifestyle changes or prevention, devices are often the only solution once a medical problem develops. Population aging does not guarantee device-company growth (hospitals and insurers still negotiate hard on price), but it provides a long-term demand backdrop.

The sector is not without pressures. Hospital consolidation has given large health systems more negotiating leverage, pushing device makers to accept lower prices. Regulatory scrutiny (especially around hip and knee implants after quality scandals) adds compliance cost and slows innovation cycles. Competition from international device makers, especially from lower-cost Asian manufacturers, is rising. And like pharma, device companies depend on having new innovations to drive growth, because older products mature and face price pressure. A company that stops innovating will see its growth slow and its margins compress.

The business is also capital-intensive. A device company might spend 10–15% of revenue on research and development, and the regulatory pathway (FDA approval, clinical trials) is long and expensive. A surgical robot company like Intuitive Surgical spends huge sums to iterate on its platform. An orthopedic-implant company needs to continually develop new materials, designs, and sizing options to stay ahead of competitors. This limits the universe of winners — only well-capitalized, strategically sound companies can sustain the R&D required to stay competitive.

Within the device world, there are also subsectors with different dynamics. Orthopedic implants (hips, knees, spine) are high-volume, mature, and subject to intense price competition, which is why margins in orthopedics have compressed over the past 10–15 years. Cardiac devices (pacemakers, defibrillators, ablation catheters) are higher-margin because they are often life-saving and patients cannot shop around once they need one. Diagnostic equipment (MRI, ultrasound, lab analyzers) is a long-cycle-sales business where the buyer is usually a hospital making a capital expenditure, often financed, and needing years of service and consumables. Surgical robotics is still a growing market with strong margins, but has seen competitive entry in recent years.

IHI, holding a basket of 30–60 companies across all these subsectors, gives an investor broad exposure without the need to pick individual device winners. You are betting that hospitals and doctors will keep needing better implants and equipment, that aging populations will drive volume growth, and that the companies in the fund will maintain or improve their competitive positions. The fund’s performance will depend on both the underlying growth of device demand and the margin dynamics — whether device makers can raise prices or whether hospital negotiating power keeps them flat. Unlike a growth ETF, IHI will not offer explosive upside, but it offers steady cash flow and the exposure to a durable, recurring-revenue business model that is less vulnerable to recessions than discretionary sectors.